Biotherapeutics company PureTech Health plc (PRTC) announced Thursday that the U.S. Food and Drug Administration (FDA) has granted ...

The biotherapeutics company said the treatment, LYT-200, is being evaluated in two ongoing clinical trials. It was previously granted orphan drug designation for the treatment of acute myeloid ...

A young man has been diagnosed with acute stage 3 leukemia and urgently needs help to survive. He has appealed to the general ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

In a significant advancement for cancer research, a team of scientists from Max Planck Institute for Biology Tübingen, ...

A new study evaluating the quadratic phenotypic optimization platform shows it can accurately predict personalized drug ...

Two posters presented at the 2024 American Society of Hematology meeting reported real-world outcomes data for patients ...

SMART-101 is under clinical development by Smart Immune and currently in Phase II for Relapsed Acute Myeloid Leukemia.

QL-401 is under clinical development by QLSF Biotherapeutics and currently in Phase I for Relapsed Acute Myeloid Leukemia.

Amandeep Salhotra, MD, discussed the background and findings from a pilot trial evaluating enasidenib as post-hematopoietic ...

(Alliance News) - PureTech Health PLC on Thursday said that the US Food & Drug Administration has granted fast track designation to its antibody LYT-200 for the treatment of acute myeloid leukemia.

LYT-200 is currently being evaluated in two Phase 1/2 trials for the potential treatment of AML/MDS and head and neck cancers PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company” ...